The study, which enrolled 167 paediatric patients with GHD, demonstrated that LB03002, using LGLS’ proprietary delivery technology Biohydrix, maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months.
During LB03002 treatment, a marker of efficacy and safety in growth hormone therapy – IGF-1 levels continued to increase toward the normal range in both groups.
The study also concluded that LB03002 was well tolerated and demonstrated a sustained growth potential without excessive bone maturation.
Biopartners CEO Conrad Savoy said these positive data further confirm previously presented positive data in children with GHD from a two year comparative trial versus daily growth hormone which was followed by a one year extension.
LGLS hGH Development VP Hyi-Jeong Ji said they believe this once-a-week hGH will offer a very attractive treatment modality to endocrinologists and their patients, leading to better adherence to long-term therapy and a successful treatment outcome.